HK1256604A1 - Ezh2抑制剂和调节性t细胞功能的调制 - Google Patents

Ezh2抑制剂和调节性t细胞功能的调制 Download PDF

Info

Publication number
HK1256604A1
HK1256604A1 HK18115733.0A HK18115733A HK1256604A1 HK 1256604 A1 HK1256604 A1 HK 1256604A1 HK 18115733 A HK18115733 A HK 18115733A HK 1256604 A1 HK1256604 A1 HK 1256604A1
Authority
HK
Hong Kong
Prior art keywords
regulatory
modulation
cell function
ezh2 inhibitors
ezh2
Prior art date
Application number
HK18115733.0A
Other languages
English (en)
Chinese (zh)
Inventor
GHOSH Srimoyee
M. LORA Jose
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of HK1256604A1 publication Critical patent/HK1256604A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18115733.0A 2015-08-03 2016-07-28 Ezh2抑制剂和调节性t细胞功能的调制 HK1256604A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200244P 2015-08-03 2015-08-03
US62/200,244 2015-08-03
PCT/US2016/044409 WO2017023671A1 (en) 2015-08-03 2016-07-28 Ezh2 inhibitors and modulation of regulatory t-cell function

Publications (1)

Publication Number Publication Date
HK1256604A1 true HK1256604A1 (zh) 2019-09-27

Family

ID=56611618

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115733.0A HK1256604A1 (zh) 2015-08-03 2016-07-28 Ezh2抑制剂和调节性t细胞功能的调制

Country Status (8)

Country Link
US (1) US20180221362A1 (cg-RX-API-DMAC7.html)
EP (1) EP3331561A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018522045A (cg-RX-API-DMAC7.html)
CN (1) CN108136011A (cg-RX-API-DMAC7.html)
AU (1) AU2016302747A1 (cg-RX-API-DMAC7.html)
CA (1) CA2994394A1 (cg-RX-API-DMAC7.html)
HK (1) HK1256604A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017023671A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN110944628A (zh) * 2017-06-02 2020-03-31 Epizyme股份有限公司 使用ezh2抑制剂治疗癌症
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
US20210260051A1 (en) * 2018-06-14 2021-08-26 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
TW202027787A (zh) * 2018-09-29 2020-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｅｚｈ２抑制劑與免疫檢查點抑制劑聯合在製備治療腫瘤的藥物中的用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
CN112007162B (zh) * 2019-05-30 2023-05-12 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
CN114040776B (zh) * 2019-06-28 2024-05-14 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
JP7530420B2 (ja) * 2019-07-24 2024-08-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッド がんの治療のためのｅｚｈ２阻害併用療法
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
WO2023108563A1 (zh) * 2021-12-16 2023-06-22 北京大学第三医院（北京大学第三临床医学院） 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途
KR20240072936A (ko) * 2022-11-17 2024-05-24 인제대학교 산학협력단 Ezh2 저해제 및 항-pd-1 항체를 포함하는, 암의 예방 또는 치료용 약제학적 조성물
WO2025085536A1 (en) * 2023-10-16 2025-04-24 Lankenau Institute For Medical Research Biologic conjugates that inhibit production of inflammatory cells and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156712A1 (en) * 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
ES2528269T3 (es) * 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
AU2011298987B2 (en) * 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
ES2600161T3 (es) * 2011-11-04 2017-02-07 Glaxosmithkline Intellectual Property (No. 2) Limited Compuestos para uso en el tratamiento de enfermedades mediadas por linfocitos T
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN103690531A (zh) * 2012-09-27 2014-04-02 烟台大学 茶乙香酸等在制备具有预防和治疗癌症等疾病的产品中的应用
MA38341B1 (fr) * 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof

Also Published As

Publication number Publication date
CA2994394A1 (en) 2017-02-09
JP2018522045A (ja) 2018-08-09
AU2016302747A1 (en) 2018-02-22
CN108136011A (zh) 2018-06-08
EP3331561A1 (en) 2018-06-13
WO2017023671A1 (en) 2017-02-09
US20180221362A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
HK1256604A1 (zh) Ezh2抑制剂和调节性t细胞功能的调制
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
NZ748070A (en) Combination therapies of hdac inhibitors and pd-1 inhibitors
MY201783A (en) Compositions and methods for inhibiting arginase activity
MX2017003227A (es) Terapias de combinacion de inhibidores de alk.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX2017001154A (es) Metodos y combinaciones terapeuticas para tratar tumores.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2017012738A (es) Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
PH12018500423A1 (en) Inhibitors of ezh2
SG11202010423VA (en) COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER
MX2018002344A (es) Metodo para tratar el cancer.
MX2022006932A (es) Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
EP4309738A3 (en) Method of treating medulloblastoma with an ezh2 inhibitor
MX2017003464A (es) Inhibidores de histona desmetilasa.
EP3630080A4 (en) USE OF EZH2 INHIBITORS TO TREAT CANCER
MX390320B (es) Farmaco de combinacion.
EP4324477A3 (en) Oxabicycloheptanes for modulation of immune response
EP3856352A4 (en) Methods of treatment of cancer comprising cdc7 inhibitors